50 results on '"Khoja, Leila"'
Search Results
2. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
3. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
4. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases
5. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset.
6. Characteristics and outcomes in patients with KRAS mutated lung adenocarcinomas: a retrospective data analysis
7. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience
8. Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer
9. Extracellular vesicles from biological fluids as potential biomarkers for prostate cancer
10. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
11. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series
12. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis
13. Circulating biomarkers in hepatocellular carcinoma
14. Dabrafenib in the treatment of metastatic or unresectable melanoma
15. An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
16. 80 - Characteristics and outcomes in patients with KRAS mutated lung adenocarcinomas: a retrospective data analysis
17. Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming
18. Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
19. Multi-site clonality analyses uncovers pervasive subclonal heterogeneity and branching evolution across melanoma metastases
20. An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).
21. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma
22. AR Signaling and the PI3K Pathway in Prostate Cancer
23. Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)
24. Malignant Bowel Obstruction in Advanced Ovarian Cancer
25. P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer
26. PD-1 agent
27. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
28. The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma
29. Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016
30. Prognosticators of first line treatment for metastatic uveal melanoma (MUM).
31. Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).
32. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
33. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
34. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
35. Pembrolizumab
36. Increased Treatment-Related Toxicity Subsequent to an Anti–PD-1 Agent
37. Abstract CT226: A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma
38. Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?
39. Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM).
40. Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity.
41. Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.
42. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
43. Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer
44. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma
45. Method validation of circulating tumour cell enumeration at low cell counts
46. Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
47. Dosing of the First Cycle of Perioperative Chemotherapy in Resectable Gastroesophageal Cancer: a Retrospective Study of Prescribing in Obese Patients
48. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.
49. Pancreatic circulating tumor cells: Where are they?
50. P-0065DOSING OF THE FIRST CYCLE OF PERIOPERATIVE CHEMOTHERAPY IN RESECTABLE GASTROESOPHAGEAL CANCER: A RETROSPECTIVE STUDY OF PRESCRIBING IN OBESE PATIENTS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.